Skip to main content

Table 1 Alk, Met, and EGFR binding properties of the test tricyclic compounds

From: Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR

Compound

1

2a

2b

Kd study (nM)

 ALK

800

340

390

 MET

>1000

250

330

 EGFRLR*

420

710

780

 EGFRLR+TM§

110

110

270

Kd values comparing 1 or 6 h incubation times (nM)†

 EGFRLR (1 h)

57 (10%)

340 (14%)

170 (65%)

 EGFRLR+TM (1 h)

25 (13%)

56 (14%)

58 (170%)

 EGFRLR (6 h)

5.7

47

110

 EGFRLR+TM (6 h)

3.2

8

100

Apparent Kd values with 30× dilution after 1 h incubation (nM)‡

 EGFRLR (30× dilution)

32 (56%)

340 (100%)

2900 (5.9%)

 EGFRLR+TM (30× diution)

12 (48%)

56 (100%)

4100 (1.4%)

  1. *EGFR (L858R)
  2. §EGFR (L858R, T790M)
  3. †Percentages significantly lower than 100% indicate slow association
  4. ‡Percentages significantly higher than 3% indicate slow dissociation